Genetic And Molecular Mechanisms of NF1
Panelists discuss how mutations in the NF1 gene lead to loss of neurofibromin function, resulting in hyperactivation of the RAS/MAPK and PI3K/AKT/mTOR pathways, and how this molecular dysregulation drives abnormal cell proliferation and tumor development in NF1.
HIV Therapy Without Integrase Inhibitor: Practical Advantages and Targeted Patient Populations
May 9th 2025A panelist discusses how the new doravirine and islatravir combination offers an alternative to integrase inhibitor-based therapies, particularly useful for patients with integrase inhibitor resistance or adverse reactions, although clinicians may struggle with determining the ideal patient population.
Phase 3 HIV Treatment Switch Studies: Key Findings From Recent Clinical Trials
May 9th 2025A panelist discusses how a new drug combination of doravirine and islatravir was compared to a standard bictegravir-based therapy in patients with HIV, showing noninferiority with over 90% of patients maintaining viral suppression without excess toxicity.
Final Thoughts Alzheimer Disease Care
May 9th 2025Panelists discuss how the current Alzheimer disease treatment landscape represents both significant progress with novel amyloid-targeting therapies and ongoing challenges, while expressing hope for future advances including more potent disease-modifying treatments, combination therapies, earlier intervention capabilities, improved biomarkers, greater health care equity, and comprehensive care models that address both medical and psychosocial aspects of the disease.
Analyzing Treatment-Refractory Patients
Panelists discuss how managing bronchiectasis exacerbations involves targeted antibiotics based on sputum cultures, augmenting mucus clearance with devices, and considering surgical intervention when medical management fails.
Exploring the Impact of Bronchiectasis Exacerbations
Panelists discuss how bacterial infections, environmental triggers, and microbiome imbalances cause bronchiectasis exacerbations, leading to increased cough, phlegm, fatigue, and hemoptysis.
Lorlatinib in Focus: Survival, Brain Metastases, and Beyond
Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic non-small cell lung cancer (NSCLC), particularly regarding long-term survival, durability of response, and management of brain metastases.
Emerging Therapies: Other Strategies and Important Considerations
May 5th 2025Panelists discuss how targeted therapies for immunoglobulin A (IgA) nephropathy are advancing rapidly, with promising results from trials of B-cell modulating agents that inhibit APRIL/BAFF signaling and complement pathway inhibitors that address specific steps in the 4-hit cascade.
Lp(a) Testing: Prevalence and Strategies to Improve Uptake
Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its commonality within health plans, and how payers, population health decision makers, and provider groups can integrate Lp(a) testing into broader population health management strategies.
Comprehensive Molecular Testing in Patients With Ovarian Cancer
May 5th 2025A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for better education of health care providers and more affordable, widely available testing options.
Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment
Experts discuss how knowledge of lipoprotein(a) (Lp[a]) levels can empower patients in managing atherosclerotic cardiovascular disease (ASCVD) risk factors, how providers can collaborate with patients on Lp(a) testing and risk management, the potential population-level value of improved ASCVD risk assessment, and how the National Lipid Association’s (NLA) recommendation for one-time Lp(a) testing may benefit health systems.
Emerging Molecular Biomarkers in Ovarian Cancer
May 5th 2025A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including microsatellite instability (MSI), tumor mutational burden (TMB), HER2, p53, KRAS, and CCNE amplification.
From AAD 2025 to the Future: Advancements in Dermatology to Watch
May 5th 2025A panelist discusses how the evolving landscape of atopic dermatitis treatment is moving toward a more personalized approach that carefully balances efficacy goals with safety considerations, incorporating new targeted therapies alongside traditional options while also expressing excitement about emerging research in dermatology including novel bispecific antibodies, microbiome-based interventions, and noninvasive diagnostic technologies that may revolutionize disease management in the coming years.
The Evolution of ALK+ NSCLC Care
Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of emerging clinical data.
Emerging Anti-BAFF and Anti-APRIL Therapies
May 5th 2025Panelists discuss how novel targeted therapies for immunoglobulin A (IgA) nephropathy are transforming treatment paradigms by specifically addressing the underlying pathophysiology of the 4-hit cascade rather than broadly suppressing inflammation.
Final Panel Thoughts on Uncomplicated UTI Management
Panelists discuss how the management of uncomplicated urinary tract infections (UTIs) is evolving, with promising new therapies that address antibiotic resistance concerns, while emphasizing the continued importance of antimicrobial stewardship, personalized treatment approaches, preventive strategies, and comprehensive patient education to reduce recurrence rates and improve outcomes in this common but burdensome condition.
Addressing Concerns About the Financial Impact of Amyloid-Targeting Therapies
May 2nd 2025Panelists discuss how the substantial financial impact of amyloid-targeting therapies necessitates innovative approaches including value-based pricing models, outcomes-based contracts, risk-sharing arrangements between payers and manufacturers, stratified patient selection criteria, and system-level solutions to balance clinical benefit with economic sustainability for health care systems, insurers, and patients.
Payer-Related Barriers With Therapies Used for Uncomplicated UTIs
Panelists discuss how recurrent urinary tract infections (UTIs) treated with older antibiotics generate 2 to 3 times higher total costs than initial savings, warranting cost-effectiveness analyses in treatment decisions, whereas payers create barriers to newer therapies through restrictive authorizations, high co-pays, step therapy mandates, and limited formulary inclusion that providers can navigate via detailed documentation, pharmacy benefit manager engagement, patient assistance programs, and advocacy for evidence-based coverage policies.
Access to Diagnostic Tests and Coverage for Amyloid-Targeting Therapies: Payer Considerations
May 2nd 2025Panelists discuss how managed care organizations can improve Alzheimer diagnostic test access while navigating complex coverage challenges for amyloid-targeting therapies across traditional Medicare (with restrictive NCDs), Medicare Advantage plans, private insurance, and younger patients who face categorical exclusions despite clinical need.
Examining The Pathophysiology Of Bronchiectasis
Panelists discusses how the "vicious vortex model" explains bronchiectasis pathophysiology, where airway dilatation leads to mucus stagnation, chronic infections, and neutrophilic inflammation, worsening the condition.
Common Symptoms Seen With Bronchiectasis
Panelists discusses how bronchiectasis differs from other respiratory diseases like asthma and COPD through symptoms, imaging findings, and pathophysiological mechanisms.
Changing Patient Demographics in HIV and Impacts of Polypharmacy on Treatment
April 30th 2025A panelist discusses how the HIV patient population has aged significantly, with the average age in their clinic now exceeding 50 years and expected to soon exceed 65 years, and how these aging patients experience more comorbidities at younger ages than the general population while their HIV becomes easier to manage with simple regimens.
HIV Viral Suppression: Clinical Significance and Impact on Patient Outcomes
April 30th 2025A panelist discusses how viral suppression in HIV patients means achieving undetectable virus levels (below 50 or 20 copies per ml), which prevents immune system damage and transmission to others, summarized as "undetectable equals untransmissible" (U=U).
FRα Biomarker Testing in Patients With Ovarian Cancer
April 28th 2025A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for mirvetuximab soravtansine (an antibody-drug conjugate therapy), emphasizing the importance of comprehensive biomarker testing at diagnosis rather than piecemeal testing.
The Role of Guidelines on Molecular Testing in Ovarian Cancer
April 28th 2025A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for treatment decisions, prognostic information, and family prevention strategies.
Gaps in Patient Care for IgA Nephropathy
April 28th 2025Panelists discuss how significant gaps in immunoglobulin A (IgA) nephropathy patient care persist, including delayed diagnosis, limited access to nephrology expertise, inadequate disease monitoring, and insufficient psychosocial support throughout the disease journey.
Current Treatments for IgA Nephropathy and the 4-Hit Cascade
April 28th 2025Panelists discuss how current immunoglobulin A (IgA) nephropathy treatments primarily target downstream inflammatory pathways of the 4-hit cascade, with emerging therapies now beginning to address specific upstream mechanisms including abnormal IgA1 production, autoantibody formation, and immune complex deposition.
The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies
Experts discuss how lipoprotein(a) (Lp[a]) testing, even without targeted Lp(a)-lowering therapies, can enhance overall cardiovascular risk assessment and potentially influence the management of other risk factors.
FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels
Experts discuss FDA-approved therapies for high lipoprotein(a) [Lp[a]) levels, their benefits and shortcomings, the frequency of their use in health plans, emerging therapies in the pipeline, and the expected timeline for associated data release.
JAK Inhibitors vs Cytokine Inhibitors: AAD 2025 Findings on Infection Risks
April 28th 2025A panelist discusses how the comprehensive ADVANCES safety monitoring system data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) revealed distinct infection risk profiles between Janus kinase (JAK) inhibitors (upadacitinib/abrocitinib, n = 1686) and cytokine inhibitors (dupilumab/tralokinumab, n = 3352) in atopic dermatitis patients, with JAK inhibitors showing elevated relative risks for serious infections and Candida infections during the 180-day assessment period, potentially influencing treatment selection based on individual patient risk factors.